Hormone Refractory Prostate Cancer — TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
Citation(s)
A Randomized Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer